Blue Owl Capital Holdings LP
Top Portfolio Positions
44 positions ·
$360,324,323 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| AKTS |
Aktis Oncology, Inc.
Healthcare
|
3,161,348 | $56,556,515 | 15.70% | |
| LRMR |
Larimar Therapeutics, Inc.
Healthcare
|
7,120,007 | $32,040,031 | 8.89% | |
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
4,416,353 | $30,075,363 | 8.35% | |
| NCDL |
Nuveen Churchill Direct Lending Corp.
Financial Services
|
2,143,626 | $27,266,922 | 7.57% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
1,909,764 | $27,137,746 | 7.53% | |
| OBDC |
Blue Owl Capital Corp
Financial Services
|
2,045,070 | $22,618,474 | 6.28% | |
| MPLT |
MapLight Therapeutics, Inc.
Healthcare
|
1,005,929 | $20,450,536 | 5.68% | |
| CMPX |
Compass Therapeutics, Inc.
Healthcare
|
2,941,525 | $15,560,667 | 4.32% | |
| CNTX |
Context Therapeutics Inc.
Healthcare
|
5,089,015 | $13,333,219 | 3.70% | |
| HLLY |
Holley Inc.
Consumer Cyclical
|
4,236,888 | $13,007,246 | 3.61% |
Portfolio Trend
Holdings in PLRX
Shares Held
Position Value (USD)
10 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,741,190 | 2,969,199 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $3,622,422 | 2,969,199 | Shares | Defined | 2026-02-20 | |
| 2025-09-30 | $4,394,414 | 2,969,199 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $3,444,270 | 2,969,199 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $4,008,418 | 2,969,199 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $36,470,350 | 2,769,199 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $33,677,070 | 3,004,199 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $32,295,139 | 3,004,199 | Shares | Defined | 2024-08-15 | |
| 2024-03-31 | $44,762,565 | 3,004,199 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $54,406,043 | 3,004,199 | Shares | Defined | 2024-02-15 | |
| No 13F history on record for this holder in this stock. | ||||||